GLP-1 Prices Are Dropping: Here's the 2026 Timeline
📉 The Trajectory Is Clear
GLP-1 medication prices have fallen faster in the past 12 months than in the previous five years combined. Wegovy went from $1,349/month list price to $149/month self-pay (for the pill). Zepbound went from $1,086/month to $299/month through LillyDirect. Medicare coverage at $50/month starts July 2026. IRA-negotiated pricing hits January 2027. And new competitors are arriving. Every force in the market is pushing prices downward.
The Complete Price Drop Timeline
Here's every major GLP-1 pricing milestone — past, present, and upcoming — in chronological order.
What Already Happened
NovoCare Pharmacy Launches
Novo Nordisk begins selling Wegovy directly to consumers at $499/month — down from the $650 savings card program and far below the $1,349 list price. The first time a GLP-1 manufacturer sold directly to patients.
LillyDirect Cuts Zepbound Vial Prices
Eli Lilly drops Zepbound single-dose vials to $349 (starting dose) and $499 (higher doses) through LillyDirect. Walmart Pharmacy pickup option added.
The Big Price War Begins
Novo Nordisk slashes Wegovy/Ozempic self-pay to $349/month for all doses (from $499). Offers $199 intro price for new patients. Eli Lilly responds: Zepbound 2.5mg drops to $299 (from $349), 5mg to $399 (from $499), higher doses to $449 (from $499). Both companies sign pricing deals with the White House.
Oral Wegovy Approved + CMS Announces BALANCE
FDA approves the Wegovy pill (oral semaglutide 25mg) for obesity. CMS announces the BALANCE Model and Medicare GLP-1 Bridge — the first-ever Medicare coverage for weight-loss GLP-1s. Retatrutide TRIUMPH-4 reports 28.7% weight loss, signaling even more competition ahead.
Wegovy Pill Launches at $149/Month
NovoCare begins selling the oral Wegovy pill at $149/month — the lowest price point ever for an FDA-approved GLP-1 weight loss medication. This is cheaper than many compounded semaglutide products when you include all their hidden fees.
Where We Are Now (March 2026)
| Medication | One Year Ago | Today | Change |
|---|---|---|---|
| Wegovy (injectable) | $499/mo (NovoCare) or $1,349 list | $349/mo (NovoCare) | -30% from NovoCare launch |
| Wegovy (pill) | Didn't exist | $149/mo (NovoCare) | New — lowest ever |
| Zepbound (2.5mg) | $399/mo (LillyDirect) | $299/mo (LillyDirect) | -25% |
| Zepbound (5mg+) | $499–$549/mo | $399–$449/mo | -10 to -18% |
| Ozempic (all doses) | $499/mo or $935 list | $349/mo (NovoCare) | -30% from NovoCare launch |
What's Coming Next
BALANCE Model Medicaid Launch
Participating states begin offering GLP-1 coverage through CMS-negotiated pricing. Previously, only about 13 states covered GLP-1s for obesity under Medicaid. The BALANCE Model could expand this significantly.
Novo Introductory Offer Expires
The $199/month new-patient pricing for lowest doses of Wegovy and Ozempic ends. Regular NovoCare pricing ($349/month for injectables, $149–$199/month for pill) continues.
Medicare GLP-1 Bridge Launches
Eligible Medicare Part D beneficiaries can access Wegovy and Zepbound for $50/month. Nationwide. No plan opt-in required. The most significant expansion of GLP-1 access for older adults in history.
Wegovy Pill 4mg Promo Expires
The $149/month promotional price for the 4mg Wegovy pill increases to $199/month. Lower doses remain at $149.
Orforglipron FDA Decision
Eli Lilly's oral GLP-1 pill — if approved, it adds another competitor to the oral market. Expected pricing: $149–$399/month, directly competing with the Wegovy pill. More competition = more pricing pressure.
CagriSema FDA Decision
Novo Nordisk's next-gen semaglutide + cagrilintide combination. If approved, it provides another high-efficacy option (~25% weight loss) and increases competitive pressure on Eli Lilly's pricing.
IRA-Negotiated Semaglutide Pricing + BALANCE Part D
Two massive changes at once. Under the Inflation Reduction Act, Medicare's negotiated price for semaglutide products (Ozempic, Wegovy, Rybelsus) takes effect — estimated at approximately $274/month. Simultaneously, the BALANCE Model integrates into Medicare Part D, making GLP-1 coverage for weight management a standard benefit for participating plans.
Generic Liraglutide (Saxenda) + Retatrutide Approval
Generic liraglutide could become the first generic GLP-1 — older-generation, less effective, but cheap. Retatrutide (28.7% weight loss) gets FDA approval and launches, adding the most potent option yet to the market. More choice at every price point.
Why Prices Are Falling — And Why They'll Keep Falling
Four structural forces are driving GLP-1 prices downward, and none of them are temporary:
1. Direct competition between Novo and Lilly. For years, Novo Nordisk had the GLP-1 market largely to itself. Eli Lilly's entry with tirzepatide (Zepbound/Mounjaro) created genuine competition for the first time. Each company's price cuts have triggered responses from the other. This dynamic will only intensify as their pipelines mature.
2. Direct-to-consumer platforms bypass middlemen. NovoCare and LillyDirect eliminate the pharmacy benefit managers (PBMs) and insurance negotiations that kept list prices artificially high. When you buy from the manufacturer directly, they don't need to inflate the price to accommodate PBM rebates and pharmacy markups.
3. Government pressure is structural. The Inflation Reduction Act gives Medicare negotiating power over drug prices for the first time. Semaglutide products are among the next batch of drugs subject to negotiation, with prices taking effect in 2027. The BALANCE Model adds another lever. This isn't a one-time event — it's a permanent shift in the pricing landscape.
4. Pipeline competition is accelerating. At least five next-generation GLP-1 medications are expected to reach the market between 2026 and 2028. Each new entrant creates pressure on existing products to compete on price. When retatrutide launches at ~30% weight loss, Novo Nordisk will need to justify why existing Wegovy customers shouldn't switch — and price will be one of the tools they use.
What This Means for You
If you've been waiting for GLP-1 medications to become affordable — the wait is largely over. The Wegovy pill at $149/month, Zepbound vials at $299/month, and Medicare coverage at $50/month (starting July) have broken through the price barriers that kept most people locked out.
And the trajectory is unmistakably downward. By January 2027, IRA-negotiated pricing and the BALANCE Model will push costs lower still. By 2028, generic options and next-gen competitors will provide even more choices.
Starting treatment today with a currently available medication at today's prices doesn't lock you in. You can switch medications, switch providers, or take advantage of lower prices as they become available. What you can't get back is the time you spend waiting for prices to drop while your health conditions compound.
Compare Today's Best Prices
See real provider pricing — brand-name and compounded — updated for March 2026
View Provider Comparison → Updated March 2026